Nemdatine (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of neurodegenerative conditions that involve glutamate‑mediated excitotoxicity, primarily Alzheimer’s disease.

• Alzheimer’s disease (moderate to severe): improves cognition and daily functioning.
• Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression.
• Alzheimer’s disease (maintenance therapy): helps sustain functional abilities over time.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby limiting excitotoxic neuronal injury and supporting neuronal survival in the brain.

Adverse reactions to Memantine Hydrochloride can vary in frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Fatigue: feeling unusually tired or weak.
• Nausea: upset stomach with urge to vomit.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hallucinations or psychosis: visual or auditory disturbances.
• Cardiac arrhythmia: irregular heart rhythm noted on monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic disease: assess liver function and consider dose modification.
• History of seizures: use with caution and observe for neurologic changes.
• Concomitant CNS depressants: monitor for additive sedation.
• Pregnancy and lactation: safety not established; weigh benefits against risks.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism can increase neurotoxicity.
• High‑dose zinc supplements: may reduce absorption of memantine.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may diminish cognitive benefits.
• CNS depressants (e.g., benzodiazepines): enhanced sedation risk.
• Proton‑pump inhibitors: possible decrease in oral bioavailability.